Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Basilea Pharmaceutica has commenced its first Phase I study of Sulfactam antibiotic BAL30072, to evaluate the pharmacokinetic profile, safety and tolerability of the compound in healthy male volunteers.
Subscribe to our email newsletter
Basilea Pharma claims that BAL30072 has broad antimicrobial activity against multidrug-resistant Gram-negative ‘superbugs’ that are increasingly associated with potentially life- threatening infections in hospitals around the world.
Additionally, the compound can act like a ‘Trojan horse’ by exploiting natural nutrient uptake systems of pathogens to gain access to its intracellular target.
Basilea Pharma CEO Anthony Man said that Basilea remains focused on developing novel hospital anti-infectives targeting the medical challenge of rising drug resistance.
"BAL30072 is designed to tackle the increasing problem of antibiotic-resistance in a broad range of Gram-negative bacteria associated with a wide variety of serious and life-threatening hospital infections, Anthony Man said.